Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Prior treatment

• Prior autologous stem cell transplant (unless ≥ 3 months after transplant) or prior chimeric cell therapy (unless ≥ 6 months after cell infusion)
• Prior allogeneic stem cell transplant
  • Note: Other protocol defined Inclusion/Exclusion criteria may apply

Other illness

• Prior malignancy within the past 2 years, except for curatively treated basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast, or low risk (Gleason score ≤ 6) localized prostate cancer
• Underlying medical conditions that, in the investigator's opinion, will render the administration of study drug hazardous or obscure the interpretation of safety or efficacy results
• A known history of or currently suspected Richter's syndrome

• Participants with a histologically confirmed diagnosis of CLL/SLL based on the International Workshop on CLL (iwCLL) criteria:
  • Treatment intolerance or failure during or after treatment with chemoimmunotherapy (CIT) and BTK inhibitors (BTKi) or
  • Treatment intolerance or failure during or after treatment with BTKi for CIT-ineligible participants as assessed by the investigator.
• Participants who require treatment based on the iwCLL 2018 criteria
• Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 2
• Life expectancy of \> 6 month